Prnewswire·2026-01-09 01:57Core Viewpoint - The proposed sale of Ventyx Biosciences, Inc. to Eli Lilly and Company is under investigation to assess whether the offered price of $14.00 per share adequately reflects the company's value [1]. Group 1: Transaction Details - Shareholders of Ventyx will receive $14.00 in cash for each share they own as part of the proposed transaction [1]. - The law firm Kahn Swick & Foti, LLC is investigating the adequacy of this consideration and the process leading to the proposed sale [1]. Group 2: Legal Rights and Contact Information - Individuals who believe the transaction undervalues Ventyx or wish to discuss their legal rights can contact KSF Managing Partner Lewis S. Kahn for more information [2]. - KSF provides a toll-free number and an online resource for further inquiries regarding the case [2].